Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.

Research output: Contribution to journalArticle


Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT.


  • Terese Hylander
  • Olivia Larsson
  • Ulla Westin
  • Mia Eriksson
  • Susanna Kumlien Georén
  • Ola Winqvist
  • Lars-Olaf Cardell
External organisations
  • Karolinska Institutet
  • Skåne University Hospital
  • Karolinska University Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Respiratory Medicine and Allergy
Original languageEnglish
Article number10
JournalRespiratory Research
Issue number1
Publication statusPublished - 2016
Publication categoryResearch